Novo Nordisk is deploying artificial intelligence to dramatically shorten the drug launch timeline, with its India operations in Bengaluru emerging as a critical part of the process for global markets.
- AI reduces drug launch time from over a year to months
- Bengaluru center central to global regulatory and commercial tasks
- Selective hiring planned despite operational growth
What happened
Novo Nordisk announced that it has integrated artificial intelligence across key stages of the drug launch process to accelerate timelines significantly. Historically, the period from the last clinical trial visit to the first regulatory filing could take about 18 months. The company now reports that AI has reduced this timeframe to just a few months.
The Danish pharmaceutical company is leveraging AI tools to automate the drafting of regulatory documents, analyze safety data, and support commercial analytics for drugs that are both in clinical trials and already marketed. These efforts reflect broader industry trends toward using machine learning to streamline development and reduce costs.
Why it matters
Novo Nordisk’s use of AI to accelerate drug rollouts comes as it seeks to solidify its position in the competitive obesity drug market. Fast-tracking drug launches can provide a critical competitive advantage by delivering new therapies to patients sooner.
The company’s India operations, centered in Bengaluru, have become increasingly vital. The center now undertakes a substantial share of preparatory functions for drug launches worldwide, including for recently introduced oral obesity medications in the United States. This underlines India’s growing role as a global hub for pharmaceutical services.
What to watch next
While the Bengaluru team’s contributions continue to grow, Novo Nordisk is cautious about rapid expansion in its global business services unit. It expects to maintain around 4,000 employees by year-end, down from earlier plans to reach 5,000 by 2025, as the company refines its approach to scaling AI capabilities.
Observers should monitor how Novo Nordisk balances AI-driven efficiency with workforce needs, especially amid broader pharmaceutical industry restructuring. The impact of these advances on drug development timelines and market competition will also be key indicators of AI’s transformative potential in pharma.